Symphogen, a clinical-stage antibody oncology-focused company, pioneering the application of complex mAb mixtures for cancer therapy, based near Copenhagen, Denmark. In 2018 a collaboration between Symphogen and Thermo Fisher Scientific was established to:
Transferring bio/pharmaceutical ultra-high performance liquid chromatography (UHPLC) methods between UHPLC systems in the same lab, between labs or to an external partner lab can be challenging.
Dr. Kristensen, principal scientist for Symphogen shares his experience with the Vanquish UHPLC platform and experiences of performing complex biopharmaceutical separations between UHPLC systems within one site and in the laboratory of an external partner.
To address product complexity, and meet regulatory demands, Symphogen is looking increasingly to mass spectrometry for qualitative and quantitative control of critical quality attributes (CQAs).
Case studies employing LC MS (Multiple-Attribute Method, MAM) and native mass spectrometry for characterization and control of CQAs during biopharmaceutical development are presented.
Gain insight into cutting edge oncology drug development and learn how advanced LC-MS workflows are accelerating the drug development pipeline.
Hear Dan Bach Kristensen, Principal Scientist from Symphogen discussing native LC-MS-based lead selection studies and how Chromeleon CDS helps them to acquire, process and evaluate data with a seamless software platform.